Iran (Islamic Republic of)
Tuberculosis profile
Population  2013 77 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.5 (1.4–3.5) 3.2 (1.8–4.5)
Mortality (HIV+TB only) 0.078 (0.045–0.12) 0.1 (0.06–0.16)
Prevalence  (includes HIV+TB) 24 (12–41) 32 (16–53)
Incidence  (includes HIV+TB) 16 (13–20) 21 (17–25)
Incidence (HIV+TB only) 0.26 (0.11–0.32) 0.34 (0.14–0.41)
Case detection, all forms (%) 68 (56–83)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 5 (3.4–7) 48 (35–62)
MDR-TB cases among notified pulmonary
TB cases
370 (250–520) 360 (260–470)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 6 112   372
Pulmonary, clinically diagnosed 1 312   78
Extrapulmonary 3 113   65
       
Total new and relapse 11 052    
Previously treated, excluding relapses 307    
Total cases notified 11 359    
Among 11 052 new and relapse cases:
420 (4%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 582 (10%) 285 (35%) 867
Laboratory-confirmed RR-/MDR-TB cases     68
Patients started on MDR-TB treatment     59
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 428 (13)
HIV-positive TB patients 281 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 70 (25)
HIV-positive TB patients on antiretroviral therapy (ART) 104 (37)
HIV-positive people screened for TB 7 906  
HIV-positive people provided with IPT 150  
Treatment success rate (%)
New and relapse cases registered in 2012 87
Previously treated cases, excluding relapse, registered in 2012 84
HIV-positive TB cases, all types, registered in 2012 66
RR-/MDR-TB cases started on second-line treatment in 2011 68
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 3.6
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-24 Data: www.who.int/tb/data